ResourceClinical Diagnostics
SPEAR pTau 217 outperforms leading ultra-sensitive technology
15 Jan 2026This application note highlights how SPEAR® pTau 217, an ultra-sensitive blood-based immunoassay, delivers exceptional performance in Alzheimer’s disease research and clinical studies. Validated across more than 120 clinical plasma samples, SPEAR pTau 217 achieved 98.8% diagnostic accuracy (AUC) and demonstrated a 5.3-fold separation between Alzheimer’s and control populations, outperforming leading ultra-sensitive technologies.
Links
Tags
BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Alzheimers DiseaseNeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.ImmunoassayImmunoassays are laboratory tests that utilize antibody-antigen interactions to detect specific substances. They are widely used in diagnostics for detecting diseases, drug testing, and environmental monitoring. These assays offer rapid, sensitive, and precise detection of biomarkers, making them invaluable in clinical and research labs. Browse our peer-reviewed product directory to compare immunoassay systems, read user reviews, and get pricing directly from manufacturers.